BR112021018138A2 - Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico - Google Patents

Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico

Info

Publication number
BR112021018138A2
BR112021018138A2 BR112021018138A BR112021018138A BR112021018138A2 BR 112021018138 A2 BR112021018138 A2 BR 112021018138A2 BR 112021018138 A BR112021018138 A BR 112021018138A BR 112021018138 A BR112021018138 A BR 112021018138A BR 112021018138 A2 BR112021018138 A2 BR 112021018138A2
Authority
BR
Brazil
Prior art keywords
lymphoma
compositions
acid
benzylthiooctanoic
bis
Prior art date
Application number
BR112021018138A
Other languages
English (en)
Portuguese (pt)
Inventor
Ariela Noy
Jeffrey Edelson
S Pardee Timothy
Zanetta Lamar
Original Assignee
Memorial Sloan Kettering Cancer Center
Rafael Pharmaceuticals Inc
Univ Wake Forest Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Rafael Pharmaceuticals Inc, Univ Wake Forest Health Sciences filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112021018138A2 publication Critical patent/BR112021018138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021018138A 2019-03-19 2020-03-19 Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico BR112021018138A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820767P 2019-03-19 2019-03-19
PCT/US2020/023537 WO2020191144A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
BR112021018138A2 true BR112021018138A2 (pt) 2021-11-16

Family

ID=72519349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018138A BR112021018138A2 (pt) 2019-03-19 2020-03-19 Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico

Country Status (11)

Country Link
US (1) US20220151994A1 (https=)
EP (1) EP3941453A4 (https=)
JP (1) JP2022525779A (https=)
KR (1) KR20220018959A (https=)
CN (1) CN114040758A (https=)
AU (1) AU2020240091A1 (https=)
BR (1) BR112021018138A2 (https=)
CA (1) CA3133101A1 (https=)
MX (1) MX2021011250A (https=)
TW (1) TW202102211A (https=)
WO (1) WO2020191144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Also Published As

Publication number Publication date
KR20220018959A (ko) 2022-02-15
WO2020191144A1 (en) 2020-09-24
AU2020240091A1 (en) 2021-09-30
EP3941453A4 (en) 2022-12-28
CA3133101A1 (en) 2020-09-24
JP2022525779A (ja) 2022-05-19
TW202102211A (zh) 2021-01-16
MX2021011250A (es) 2022-02-11
US20220151994A1 (en) 2022-05-19
EP3941453A1 (en) 2022-01-26
CN114040758A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
MXPA05002791A (es) Oligonucleotidos antivirales complementarios sin secuencia.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
CY1123792T1 (el) Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια α
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
BR112022024374A2 (pt) Composições farmacêuticas de pralsetinibe
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
MX2020011817A (es) Metodos para tratar el linfoma.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2019010898A (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2022005976A (es) Compuestos antagonistas de receptores de adenosina.
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.
JOP20240197A1 (ar) أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد
EA202193178A1 (ru) Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина
BR112021018138A2 (pt) Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.